China Securities News (reporter Li Mengyang) According to the news on June 25 on the WeChat official account of "Novo Nordisk China R&D Center", recently, the National Drug Administration (NMPA) approved the listing application of Novo Nordisk's Novo Yingsheng (Smeaglutide injection solution for long-term weight management) in China.
The company stated that Novartis is the world's first and currently the only weekly preparation of glucagon like peptide-1 receptor agonist (GLP-1RA) used for long-term weight management. The approval of this innovative drug will provide a breakthrough healthy weight management plan for overweight and obese patients, opening up a new pattern of obesity treatment in China in a scientific, effective, and safe manner.
"Novo Nordisk has been conducting research in the field of obesity treatment for over 25 years. Based on the GLP-1RA therapy, the company has built a solid scientific foundation. We focus on the overall health issues of obesity patients and hope to provide them with comprehensive integrated treatment plans. In the future, we will continue to lead innovative breakthroughs in the field of obesity treatment to meet the diverse medical needs of Chinese patients," said Zhang Kezhou, Vice President of the Pharmaceutical Quality Department of Novo Nordisk Greater China